Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by David J.B. Hsiang
Diagnostic Performance of Magnetic Resonance Imaging for Assessing Tumor Response in Patients With HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy Is Associated With Molecular Biomarker Profile
Clinical Breast Cancer
Cancer Research
Oncology
Related publications
The Role of Magnetic Resonance Imaging in Assessing Residual Disease and Pathologic Complete Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: A Systematic Review
Insights into Imaging
Nuclear Medicine
Radiology
Imaging
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
New England Journal of Medicine
Medicine
Magnetic Resonance Imaging Tumor Regression Shrinkage Patterns After Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: Correlation With Tumor Biological Subtypes and Pathological Response After Therapy
Tumor Biology
Medicine
Cancer Research
Role of Magnetic Resonance Imaging in the Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy
In Vivo
Biochemistry
Medicine
Genetics
Pharmacology
Molecular Biology
MRP1 but Not MDR1 Is Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Disease Markers
Biochemistry
Medicine
Clinical Biochemistry
Molecular Biology
Genetics
Magnetic Resonance Imaging Features of Breast Cancer According to Intrinsic Subtypes: Correlations With Neoadjuvant Chemotherapy Effects
SpringerPlus
Multidisciplinary
Complete Pathological Response in Patients With Locally Advanced Cancer of Breast and Positive Her2/Neu With Neoadjuvant Chemotherapy
BMC Cancer
Cancer Research
Oncology
Genetics
RB-Pathway Disruption Is Associated With Improved Response to Neoadjuvant Chemotherapy in Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Indoleamine-2,3-Dioxygenase and Interleukin-6 Associated With Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer
Oncotarget
Oncology
